Anales de la RANM

279 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 ENVEJECIMIENTO Y ENFERMEDADES CARDIOVASCULARES José Ramón de Berrazueta Fernández An RANM · Año 2018 · número 135 (03) · páginas 266 a 280 and controversies. J Gerontol A Biol Sci Med Sci 2007; 62:731-737. doi:10.1093/ gerona/62.7.731. 16. Selye H. The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol Metab. 1946;6:117-230. 17. Yusuf S, Hawken S, Ôunpuu S, et al, "Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study," Lancet, 2004; 364 (9438): 937-952. 18. Rosengren A, Hawken S, Ounpuu S, et al, for the INTERHEART investigators. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364 (9438):953-962. 19. Franceschi C, Garagnani P, Morsiani C et al. The Continuum of Aging and Age-R ated Diseases: Common Mechanisms but Different Rates. Front. Med. 5:61. doi: 10.3389/fmed.2018.00061. 20. Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell (2014) 159(4):709–713. doi:10.1016/j. cell.2014.10.039. 21. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The Hallmarks of Aging. Cell 2013;153:1194-1217.DOI: (10.1016/j .cell. 2013.05.039. 22. Franceschi C, Garagnani P, Morsiani C et al. The Continuum of Aging and Age-R ated Diseases: Common Mechanisms but Different Rates. Front. Med. 5:61. doi: 10.3389/fmed.2018.00061. 23. Ocampo, JM; Gutiérrez, J. Envejecimiento del sistema cardiovascular .Rev. Col. Cardiol. 2005; 12: 53-63. 24. Ribera Casado JM. ¿Sabemos más cosas acerca del envejecimiento cardiaco?. En El mundo cambiante de la cardiología geriátrica. Edit: JM Ribera Casado, Pedro Gil Gregorio. Clínicas Geriátricas Madrid. Editores Médicos SA. Madrid. 2006. pp11-24. 25. Ross R. Atherosclerosis — An Inflammatory Disease. N Engl J Med 1999; 340:115-126. 26. Pearson TA, Mensah GA, Alexander RW et al. Markers of Inflammation and Cardiovascular Disease Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511. 27. Berrazueta JR. Fisiopatología de la disfunción endotelial. En Endotelio vascular y estatinas. Ed: José Tuñón y Jesús Egido. Madrid Ed Línea de Comunicación- Madrid. ISBN 84-933399-6-2. 2005. 28. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-135. 29. Ridker PM1, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH.. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. NEngJ Med 1997;336:973-979. 30. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. Eur Heart J (2017) 38, 1717– 1727 31. Van Linthout S, Tschöpe C. Inflammation - Cause or Consequence of Heart Failure or Both? Curr Heart Fail Rep. 2017;14:251-265. doi: 10.1007/ s11897-017-0337-9. 32. Kodali SK, Velagapudi P, Hahn RT, Abbott D, Leon MB. Valvular Heart Disease in Patients ≥80 Years of Age. J Am Coll Cardiol. 2018 8;71(18):2058-2072. doi: 10.1016/j.jacc.2018.03.459. 33. Ference BA, Ginsberg HN, Graham I et al, Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement fromthe EuropeanAtherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459- 2472. doi: 10.1093/eurheartj/ehx144. 34. Packard CJ. . LDL cholesterol: How low to go?. Trends Cardiovasc Med. 2018;28:348-354. doi: 10.1016/j.tcm.2017.12.011. 35. Ridker PM. HowCommon Is Residual Inflammatory Risk?. Circ Res. 2017 ;120:617-619. doi: 10.1161/ CIRCRESAHA.116.310527. 36. Ridker PM, Everett BM, Thuren T, et al for the CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017; 377:1119-1131. DOI: 10.1056/ NEJMoa1707914. 37. Moncada S. Adventures in pharmacology, aspirin, prostacyclin and nitric oxide. Acta Cardiol. 2004;59 Suppl 1:47-50. 38. Bunting S, Moncada S, Vane JR. The prostacyclin- -thromboxane A2 balance: pathophysiological and therapeutic implications. Br Med Bull. 1983 39:271- 276. 39. Patrono C, Garcia Rodriguez LA, Landolfi R, M.D., Baigent C, Low-Dose Aspirin for the Prevention of Atherothrombosis. N Engl J Med 2005;353:2373- 2383, 40. McNeil JJ, Woods R, Nelson MR, et al, for the ASPREE Investigator Group. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly . N Engl J Med 2018;379:1519-1528. DOI: 10.1056/ NEJMoa1803955. 41. McNeil JJ, Wolfe R, Woods RL, et al for the ASPREE Investigator Group. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med 2018; 379:1509-1518 DOI: 10.1056/NEJMoa1805819. 42. The ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018;379:1529- 1539. DOI: 10.1056/NEJMoa1804988). 43. Mahmoud AN, Gad MM , Elgendy AY, Elgendy IY, Bavry AA. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta- analysis and trial sequential analysis of randomized controlled trials. European Heart J (2018) 1–11 doi:10.1093/eurheartj/ehy813. 44. Spencer FA , Guyatt G. Aspirin in the primary prevention of cardiovascular disease and cancer . UpToDate. last updated: Nov 02, 2018. 45. Li Y, Pan A, Wang DD, et al. Impact of Healthy Lifestyle Factors on Life Expectancies in the US Population. Circulation. 2018;137. DOI: 10.1161/ CIRCULATIONAHA.117.032047 . 46. Duck-chul Lee, Carl J. Lavie, Rajesh Vedanthan. Optimal Dose of Running for Longevity : Is More Better or Worse? JACC 2015 65: 420-422.